Clinical trials: All
Multiple Sclerosis
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
The purpose of this study is to evaluate the safety and efficacy of Copaxone subcutaneous injection syringe (hereinafter referred to as Copaxone) in patients with multiple sclerosis in the routine clinical setting.
- Trial name
- NCT03209479
- Testing
- Glatiramer acetate
- Where
- Japan
- Volunteers
- 1,332 people
- Sponsor
- Teva Takeda Pharma Ltd.
Hemorrhage
All-Case Surveillance of Prizbind®
To evaluate safety and effectiveness of Prizbind® for Intravenous Solution 2.5 g under Japanese clinical condition.
- Trial name
- NCT02946931
- Testing
- Prizbind®
- Where
- Japan
- Volunteers
- 1,402 people
- Sponsor
- Boehringer Ingelheim
Hepatocellular Carcinoma, Prostate Cancer
LTFU for All Cell and Gene Therapy Studies
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
- Trial name
- LOCUS (NCT06194461)
- Testing
- AZD5851, AZD0754
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Relapsed or Refractory Lymphoma Including ENKL
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose…
- Trial name
- NCT06761677
- Testing
- Brincidofovir
- Where
- 8 sites in China, Japan and 1 more
- Volunteers
- 43 people
- Sponsor
- SymBio Pharmaceuticals
Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL
Primary Objective: To estimate the incidence of treatment-emergent and treatment-related adverse events during treatment with blinatumomab in pediatric and adolescent subjects with B-precursor ALL in second or later bone marrow…
- Trial name
- RIALTO (NCT02187354)
- Testing
- Blinatumomab, Extension of LTFU as per ProtocolAmendment7 7Jun18
- Where
- 19 sites in United States, Austria and 5 more
- Sponsor
- Amgen
Autism
An Open Label Study of CM-AT for the Treatment of Children With Autism
This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.
- Trial name
- NCT02649959
- Testing
- CM-AT
- Where
- 31 sites in United States
- Volunteers
- 405 people
- Sponsor
- Curemark
Lymphoma
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these…
- Trial name
- NCT00460460
- Testing
- AZD4877
- Where
- 3 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Breast Cancer
Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223
This study aims to understand better the effective results from the IMELDA MO22223 P-trial (NCT00929240) and see if the anti-cancer therapies given during its follow-up time after study treatments were terminated possibly had an…
- Trial name
- NCT02383576
- Testing
- No Intervention
- Where
- 32 sites in Brazil, France and 4 more
- Volunteers
- 185 people
- Sponsor
- Hoffmann-La Roche
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Translation: This clinical trial is designed as a single-arm, open-label, multicenter study. After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T…
- Trial name
- NCT07188610
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Covid19, Corona Virus Infection
A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit
To evaluate the performance of the FDA EUA authorized Lucira COVID-19 All-In-One Test Kit for the qualitative detection of SARS-CoV-2 virus in nasal swab samples as compared to a known high sensitivity EUA RT-PCR among…
- Trial name
- NCT04720235
- Testing
- Lucira COVID-19 All-In-One test kit
- Where
- United States
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Lucira Health Inc
Solid Tumor, Adult, Healthy Donors
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers.
- Conditions
- Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
- Trial name
- NCT00571389
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- BioCytics, Inc.
Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
- Conditions
- Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00100152
- Testing
- MK0752, (Notch Inhibitor)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Artery Disease (CAD)
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
After a stent procedure, it is common practice to prescribe anti-platelet medication to prevent the blood from clotting. The main objective of this study is to determine if there is a better medication strategy to prevent blood…
- Trial name
- NCT01813435
- Testing
- Ticagrelor, Acetylsalicylic Acid, Clopidogrel
- Where
- 130 sites in Australia, Austria and 16 more
- Volunteers
- 15,991 people
- Sponsor
- ECRI bv
Adult T-cell Leukemia/Lymphoma
Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).
- Trial name
- NCT04102150
- Testing
- Valemetostat Tosylate
- Where
- 24 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Osseous Paget's Disease
Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -
The purpose of this study is to evaluate the safety and efficacy of sodium risedronate tablets administered once daily (one tablet per dose) in patients with osseous Paget's disease for 48 weeks from baseline in daily medical…
- Trial name
- NCT02106455
- Testing
- Sodium risedronate
- Where
- 2 sites in Japan
- Volunteers
- 315 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Insulin Glargine "All to Target" Trial
The primary objectives were: To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra® (Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of patients achieving target glycemic…
- Trial name
- NCT00384085
- Testing
- Insulin Glulisine, Insulin Glargine, Premixed Insulin
- Where
- United States
- Volunteers
- 588 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive…
- Trial name
- NCT00614055
- Testing
- insulin degludec/insulin aspart, insulin glargine, metformin
- Where
- 28 sites in France, Germany and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Pharmacogenomics, Medication Therapy Management
A Pharmacist Implemented Pharmacogenomics Service in the Program of All-inclusive Care for the Elderly
The aim of this study is to evaluate and describe the feasibility of implementing a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.
- Trial name
- PACE (NCT03257605)
- Volunteers
- 296 people
- Sponsor
- Tabula Rasa HealthCare
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
- Conditions
- Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
- Trial name
- NCT06034275
- Testing
- VIP943 (QW), VIP943 (BIW)
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vincerx Pharma, Inc.
Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB)…
- Conditions
- Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- UCBT (NCT01930162)
- Testing
- HSC835
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals